Allergan Must Face Suit Over Botox Labeling: 9th Circ.
Allergan Inc. will have to face a derivative suit alleging its board improperly marketed the cosmetic drug Botox for off-label uses, the Ninth Circuit ruled Tuesday, finding the plaintiffs had alleged...To view the full article, register now.
Already a subscriber? Click here to view full article